Meteneprost amantadine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 577231

CAS#: 65470-21-5

Description: Meteneprost amantadine is a compound tested for use as an early pregnancy terminator and is a derivative of both PGE2 & PGF2alpha.

Chemical Structure

img
Meteneprost amantadine
CAS# 65470-21-5
Instruction

Theoretical Analysis

MedKoo Cat#: 577231
Name: Meteneprost amantadine
CAS#: 65470-21-5
Chemical Formula: C33H55NO4
Exact Mass: 529.41
Molecular Weight: 529.810
Elemental Analysis: C, 74.81; H, 10.46; N, 2.64; O, 12.08

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Meteneprost amantadine

IUPAC/Chemical Name: Tricyclo(3.3.1.13,7)decan-1-amine, (5Z,11alpha,13E,15R)-11,15-dihydroxy-16,16-dimethyl-9-methyleneprosta-5,13-dien-1-oate

InChi Key: ZBSKOIJDKLVUEG-PWOMVKEHSA-N

InChi Code: InChI=1S/C23H38O4.C10H17N/c1-5-6-15-23(3,4)21(25)14-13-19-18(17(2)16-20(19)24)11-9-7-8-10-12-22(26)27;11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7,9,13-14,18-21,24-25H,2,5-6,8,10-12,15-16H2,1,3-4H3,(H,26,27);7-9H,1-6,11H2/b9-7-,14-13+;/t18-,19+,20+,21+;/m0./s1

SMILES Code: CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=C)[C@@H]1C\C=C/CCCC(=O)O.NC23CC4CC(CC(C4)C2)C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 529.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: A multicentre randomized comparative clinical trial of 200 mg RU486 (mifepristone) single dose followed by either 5 mg 9-methylene PGE(2) gel (meteneprost) or 600 microg oral PGE(1) (misoprostol) for termination of early pregnancy within 28 days of missed menstrual period. ICMR Task Force Study. Indian Council of Medical Research. Contraception. 2000 Sep;62(3):125-30. PubMed PMID: 11124359.

2: Kimball FA, Cornette JC, Bundy GL, Kirton KT. Plasma concentrations of 9-deoxo-16-dimethyl-9-methylene-PGE2 in rhesus monkeys after administration by various routes. Prostaglandins. 1980 Sep;20(3):559-69. PubMed PMID: 7422900.

3: Shapiro AG, Lasseter K, Cobiella A, Domenzain M. Intravaginal administration of 9-deoxo-9-methylene-16,16-dimethyl PGE2 for cervical dilation prior to suction curettage. Int J Gynaecol Obstet. 1982 Apr;20(2):137-40. PubMed PMID: 6125434.

4: Brenner PF, Marrs RP, Roy S, Mishell DR Jr. Termination of early gestation with 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2. Contraception. 1982 Sep;26(3):261-77. PubMed PMID: 6184197.

5: Nyholm HC, Mikkelsen AL, Secher NJ. Pretreatment of the cervix with 9-deoxy-16,16-dimethyl-9-methylene-prostaglandin E2 (Meteneprost) vaginal pessaries before first trimester legal abortion in nulliparae. J Obstet Gynaecol (Lahore). 1988;8(3):210-3. PubMed PMID: 12342310.